Comparative Pharmacology
Head-to-head clinical analysis: DAYBUE versus DAYBUE STIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAYBUE versus DAYBUE STIX.
DAYBUE vs DAYBUE STIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DAYBUE (trofinetide) is a synthetic analog of the N-terminal tripeptide of insulin-like growth factor 1 (IGF-1). Its exact mechanism is unknown, but it is thought to reduce neuroinflammation and normalize synaptic function.
Gamma-aminobutyric acid (GABA) aminotransferase inhibitor; increases brain GABA levels.
Initial: 100 mg orally twice daily; titrate by 50 mg twice daily weekly to target maintenance dose of 200 mg twice daily. Maximum 200 mg twice daily.
Administer orally as 15 mg/day for 1 week; increase to 30 mg/day for 1 week; then to 45 mg/day for 1 week; final maintenance dose is 60 mg/day.
None Documented
None Documented
Terminal elimination half-life is 3–4 hours in healthy adults; 4–6 hours in patients with renal impairment (CrCl <30 mL/min). Dose adjustment needed in renal impairment.
Terminal elimination half-life: 11-14 hours; requires twice-daily dosing for sustained trough concentrations
Primarily excreted unchanged in urine (~70% in 24 hours) via active renal secretion and glomerular filtration; ~30% metabolized in liver to inactive metabolites and excreted in bile/feces.
Renal: ~70% unchanged; fecal: ~20%; biliary: <5%
Category C
Category C
Rett Syndrome Therapeutic
Rett Syndrome Therapeutic